CTCs in Cervix Cancer

Inclusion criteria

• Able to safely provide 15 ml of blood
• Able to provide informed consent
• Pathologically confirmed invasive cervical cancer
• Proof of serotype HPV 16 or HPV 18 positive within 3 years of the study
• Patients with stages IIA2 to IVB OR recurrent cervical cancer
• For patients with newly diagnosed cervical cancer, they must be enrolled (blood drawn) prior to initiating anti-cancer therapy
• For patients with recurrent cervical cancer, they must be enrolled (blood drawn) prior to initiating a new anti-cancer therapy for progression of disease (based on RECIST 1.1 criteria). Patients who have progressed and are moving to best supportive care are eligible.
• If patients meet criteria 5.1A 5 above, the following criteria must be met:
• At least 21 days have elapsed following treatment with cytotoxic chemotherapy
• At least 14 days have elapsed following treatment with biologic therapy
• At least 14 days have elapsed following radiation therapy

Exclusion criteria

• History of any cancer other than cervix cancer within the past five years.
• History of any known germ-line pathogenic mutation (ie BRCA 1 / 2 or Lynch syndrome, but genetic testing is not required)
• Current use of systemic corticosteroids at doses exceeding 10 mg per day of prednisone or its equivalent.
• Active infection including hepatitis B, hepatitis C, HIV.
• Any patient unable to comply with the study criteria.
• Patients taking any anti-inflammatory agents (aspirin, NSAIDs, steroids), within 24 hrs prior to blood draw.